Search research articles
Contact Us
Filters
Showing results (301-310 of 325) with videos related to
Page
of 33
Sort By:
The Lancet. Oncology
|
November 2, 2019
Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts
Rengaswamy Sankaranarayanan, Partha Basu, Prabhdeep Kaur, et al.
Journal of the International AIDS Society
|
July 9, 2024
Cervical cancer prevention and care in HIV clinics across sub-Saharan Africa: results of a facility-based survey
Serra Lem Asangbeh-Kerman, Maša Davidović, Katayoun Taghavi, et al.
The Lancet. Oncology
|
November 10, 2023
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial
Hitt Sharma, Sameer Parekh, Pramod Pujari, et al.
Journal of Personalized Medicine
|
July 27, 2024
Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey
Katharina Beyer, Renée C A Leenen, Lionne D F Venderbos, et al.
European Urology
|
May 24, 2024
Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe
Pieter Vynckier, Lieven Annemans, Sarah Raes, et al.
The Lancet. Oncology
|
July 8, 2015
Recommendations for screening and early detection of common cancers in India
Preetha Rajaraman, Benjamin O Anderson, Partha Basu, et al.
European Urology
|
August 25, 2024
Prostate Cancer Early Detection in the European Union and UK
Renée C A Leenen, Lionne D F Venderbos, Jozien Helleman, et al.
Vaccine
|
August 25, 2022
Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021-March 2022
Holly J Prudden, Sharon L Achilles, Celina Schocken, et al.
International Journal of Cancer
|
June 8, 2026
Clinical Validation of Four Point-of-Care High-Risk HPV Assays, Including Two Reduced-Valency Assays, for Cervical Cancer Screening in Low-Resource Settings
Neerja Bhatla, MaryLuz Rol, Seema Singhal, et al.
Eclinicalmedicine
|
July 9, 2020
Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15-25 years: A phase IV randomized comparative study
Nicolas Folschweiller, Julio Teixeira, Smita Joshi, et al.
Page
of 33
Search research articles
Search
Showing results (301-310 of 325) with videos related to
Sort By:
Page
of 33
The Lancet. Oncology
|
November 2, 2019
Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts
Rengaswamy Sankaranarayanan, Partha Basu, Prabhdeep Kaur, et al.
Journal of the International AIDS Society
|
July 9, 2024
Cervical cancer prevention and care in HIV clinics across sub-Saharan Africa: results of a facility-based survey
Serra Lem Asangbeh-Kerman, Maša Davidović, Katayoun Taghavi, et al.
The Lancet. Oncology
|
November 10, 2023
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial
Hitt Sharma, Sameer Parekh, Pramod Pujari, et al.
Journal of Personalized Medicine
|
July 27, 2024
Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey
Katharina Beyer, Renée C A Leenen, Lionne D F Venderbos, et al.
European Urology
|
May 24, 2024
Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe
Pieter Vynckier, Lieven Annemans, Sarah Raes, et al.
The Lancet. Oncology
|
July 8, 2015
Recommendations for screening and early detection of common cancers in India
Preetha Rajaraman, Benjamin O Anderson, Partha Basu, et al.
European Urology
|
August 25, 2024
Prostate Cancer Early Detection in the European Union and UK
Renée C A Leenen, Lionne D F Venderbos, Jozien Helleman, et al.
Vaccine
|
August 25, 2022
Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021-March 2022
Holly J Prudden, Sharon L Achilles, Celina Schocken, et al.
International Journal of Cancer
|
June 8, 2026
Clinical Validation of Four Point-of-Care High-Risk HPV Assays, Including Two Reduced-Valency Assays, for Cervical Cancer Screening in Low-Resource Settings
Neerja Bhatla, MaryLuz Rol, Seema Singhal, et al.
Eclinicalmedicine
|
July 9, 2020
Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15-25 years: A phase IV randomized comparative study
Nicolas Folschweiller, Julio Teixeira, Smita Joshi, et al.
Page
of 33